Navigation Links
Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors
Date:7/27/2009

SOUTH SAN FRANCISCO, Calif., July 27 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Helen S. Kim has been appointed to the company's Board of Directors, effective immediately. Ms. Kim is a designee of New Enterprise Associates, which purchased approximately $2.3 million of the company's securities in the initial closing of the company's recent private placement.

"We are pleased to have Helen join the Sunesis Board of Directors," said Daniel Swisher, Sunesis' Chief Executive Officer. "Helen brings a wealth of experience in corporate development as well as strategic marketing. We believe Helen's proven leadership, successful business development track record and commercial insights will benefit Sunesis significantly."

Ms. Kim is currently a Director and Chief Executive Officer of privately held TRF Pharma, Inc. Previously, she was the Chief Executive Officer and President of Kosan Biosciences Incorporated where she restructured and repositioned the company prior to successfully selling the company to Bristol-Myers Squibb in 2008. Ms. Kim's additional industry experience includes senior positions at Affymax, Onyx Pharmaceuticals, Protein Design Labs and Chiron Corporation. In addition to her industry experience, Ms. Kim also recently served as Chief Program Officer for the Gordon and Betty Moore Foundation from 2003 to 2008. Ms. Kim received a B.S. in Chemical Engineering from Northwestern University and a M.B.A. from the University of Chicago.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of hematologic and solid cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

    Investor Contact:                    Media Contact:
    Sunesis Pharmaceuticals, Inc.        Sunesis Pharmaceuticals, Inc.
    Eric Bjerkholt                       Dan Weinseimer
    650-266-3717                         650-266-3739



'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
5. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
8. Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
9. Sunesis Reports Financial Results for the First Quarter 2009
10. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO
11. Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... 2016 , ... Norwood Insurance Group, serving families of Dallas ... ongoing community enrichment program. The current campaign is being extended to continue fundraising ... months of treatments, leaving his family in great need of financial assistance. Donations ...
(Date:5/6/2016)... , ... May 06, 2016 , ... US Sports Camps ... rugby camp held at Oregon State University this summer. Employing world-class rugby figures, including ... of all skill levels with training on key fundamentals, match play, fitness and more. ...
(Date:5/6/2016)... ... May 06, 2016 , ... Logically, spring weather, with its moderate humidity ... is too cold, dry or hot, water on the eye surface can evaporate, creating ... the surrounding air. There’s only one problem, according to radio show and water advocate ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... The International ... Resort on the north end of the island close to the town famous for ... August 10th 2016. , “We continue to have an amazing experience in Greece, ...
(Date:5/6/2016)... ... May 06, 2016 , ... In honor ... education and corporate training, and the National Military Family Association, a nonprofit that ... as the second full-tuition scholarship recipient of 2016. , “Being awarded this ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 ... of Jerusalem announced today that it had signed ... BioTheryX, Inc. , developer of novel protein degradation and ... development and commercialization of drug candidates representing first-in-class therapy ... license were not disclosed. The novel technology ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Multiple Myeloma Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Multiple Myeloma epidemiology, Multiple Myeloma market valuations ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Actinic Keratosis Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Actinic Keratosis market valuations and forecast, ...
Breaking Medicine Technology: